Wall Street analyst estimates for BioXcel Therapeutics, Inc. (BTAI): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-1.01 | ||
| 2026-08-13 | $-0.49 | $-0.44 | -11.4% |
| 2026-05-15 | $-0.54 | $-0.59 | +8.5% |
| 2026-03-26 | $-0.58 | $-0.34 | -70.6% |
| 2025-11-12 | $-2.18 | $-1.54 | -41.6% |
| 2025-08-12 | $-2.45 | $-2.30 | -6.5% |
| 2025-05-12 | $-1.50 | $-2.72 | +44.9% |
| 2025-03-27 | $-3.57 | $-4.36 | +18.1% |
Valuation Ratios
| Price / Book | -0.01 |
| EV / EBITDA | -1.76 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | $375000 | $1.4M | $2.3M | $642000 |
| Cost of Revenue | 0 | $1000 | $17000 | $156000 | 0 | 0 | $20000 | $1.3M | $2.1M | $164000 |
| Gross Profit | 0 | -$1000 | -$17000 | -$156000 | 0 | 0 | $355000 | $120000 | $123000 | $478000 |
| Research & Development | $1.4M | $2.7M | $14.6M | $25.8M | $58.5M | $52.7M | $91.2M | $84.3M | $30.4M | $30.3M |
| Selling, General & Admin | $721000 | $1.8M | $5.4M | $7.8M | $24.6M | $54.2M | $68.8M | $83.4M | $34.5M | $20.5M |
| Operating Expenses | $2.1M | $4.5M | $20.0M | $33.6M | $82.3M | $106.9M | $160.0M | $171.9M | $67.4M | $50.7M |
| Operating Income | -$2.1M | -$4.5M | -$20.0M | -$33.6M | -$82.3M | -$106.9M | -$159.6M | -$171.8M | -$67.2M | -$50.3M |
| EBITDA | 0 | -$4.5M | -$19.3M | -$32.8M | -$82.1M | -$106.6M | -$157.2M | -$165.4M | -$44.2M | -$52.6M |
| Interest Expense | 0 | $2000 | 0 | 0 | $27000 | $40000 | $8.2M | $13.3M | $15.1M | $17.0M |
| Pre-tax Income | -$2.1M | -$4.5M | -$19.3M | -$33.0M | -$82.2M | -$106.9M | -$165.8M | -$179.1M | -$59.6M | -$69.9M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$2.1M | -$4.5M | -$19.3M | -$32.3M | -$82.2M | -$106.9M | -$165.8M | -$179.1M | -$59.6M | -$69.9M |
| EPS | $-2.06 | $-4.41 | $-21.16 | $-32.38 | $-60.63 | $-64.87 | $-94.67 | $-98.35 | $-23.51 | $-5.73 |
| EPS (Diluted) | $-2.06 | $-4.41 | $-21.16 | $-32.38 | $-60.63 | $-64.87 | $-94.67 | $-98.35 | $-23.51 | $-5.73 |
| Shares Outstanding (Diluted) | $1.0M | $1.0M | $910722 | $1.0M | $1.4M | $1.6M | $1.8M | $1.8M | $2.5M | $12.2M |
Price
| Price | $0.07 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ANVS · BCAB · CELU · EVAX · GBIO · MAIA · MURA
Explore sector: Healthcare · Biotechnology
More sections of BTAI: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks